Special lssues
Table of Content

Novel Biomarkers in Diseases for Detection, Diagnosis, and Prognosis

Submission Deadline: 31 May 2024 (closed) Submit to Special Issue

Guest Editors

Ziheng Wang, Centre for Precision Medicine Research and Training, Faculty of Health Sciences, University of Macau, China. wang.ziheng@connect.um.edu.mo

Jianfei Huang, Department of Clinical Biobank, Affiliated Hospital of Nantong University & Medical School of Nantong University, China. jfhuang@ntu.edu.cn

Summary

Biomarkers are biochemical indicators that can mark changes or possible changes in the structure or function of systems, organs, tissues, cells, and sub-cells and have a very wide range of uses. Biomarkers can be used to diagnose disease, determine disease stage, or evaluate the safety and efficacy of new drugs or therapies in target populations. The aim of this research project is to collect recent advances in basic and clinical research, dissect the molecular pathology of disease, investigate etiology and pathogenesis, and identify humoral, genetic, and imaging biomarkers for clinical settings for disease detection, diagnosis, prognosis, and prediction.

 

- Detection and identification of novel biomarkers of diseases

- Genetic biomarkers of diseases

- Epigenetic biomarkers of diseases

- Related molecular pathways

- Related Clinical Trials

- Novel biomarkers via bioinformatics analysis


Keywords

Biomarker, Diagnosis, Prognosis, Detection, Drug

Published Papers


  • Open Access

    ARTICLE

    Evaluation of combined detection of nuclear factor erythroid 2-related factor 2 and glutathione peroxidase 4 in primary hepatic carcinoma and preliminary exploration of pathogenesis

    JIE DUAN, AIDONG GU, WEI CHEN, CHANGHAO CHEN, FANGNAN SONG, FAXI CHEN, FANGFANG JIANG, HUIWEN XING
    BIOCELL, Vol.47, No.12, pp. 2609-2615, 2023, DOI:10.32604/biocell.2023.042472
    (This article belongs to the Special Issue: Novel Biomarkers in Diseases for Detection, Diagnosis, and Prognosis)
    Abstract Objective: This study aims to analyze the clinical significance and mechanism of nuclear factor erythroid 2-related factor 2 (NRF2) and glutathione peroxidase 4 (GPX4) in primary hepatic carcinoma (PHC). Methods: The expression of NRF2 and GPX4 in peripheral blood of patients with PHC was determined to analyze the diagnostic value of the two combined for PHC. The prognostic significance of NRF2 and GPX4 was evaluated by 3-year follow-up. Human liver epithelial cells THLE-2 and human hepatocellular carcinoma cells HepG2 were purchased, and the expression of NRF2 and GPX4 in the cells was determined. NRF2 and GPX4… More >

    Graphic Abstract

    Evaluation of combined detection of nuclear factor erythroid 2-related factor 2 and glutathione peroxidase 4 in primary hepatic carcinoma and preliminary exploration of pathogenesis

  • Open Access

    ARTICLE

    SIRT2 interacts with DDX24 to promote nasopharyngeal carcinoma growth

    HAIYING YUE, CHUNHUI WANG, HUIJUN ZHU, QINGHUA DU, JIAN LI, XUE OU, XIANGDE LI, QIULU ZHONG, YITING XIE, DANJING LUO, YIHE LI, CHUNXIAO LIANG, XUEMEI XU, SONGNAN DU, WENQI LIU
    BIOCELL, Vol.47, No.11, pp. 2445-2452, 2023, DOI:10.32604/biocell.2023.042512
    (This article belongs to the Special Issue: Novel Biomarkers in Diseases for Detection, Diagnosis, and Prognosis)
    Abstract Background: Nasopharyngeal carcinoma (NPC) is one of the most prevalent cancers in Southeast Asia. Sirtuin 2 (SIRT2) is a member of the NAD+-dependent deacetylase family and has been shown to play important roles in numerous biological processes. However, Its function in NPC remains uncertain. The primary aim of this study is to clarify the role of SIRT2 in NPC. Methods: In this research, we examined the effect of SIRT2 silencing on NPC cell proliferation and colony formation using vitro NPC cell lines. Co-immunoprecipitation and mass spectrometry was applied to identify SIRT2-interacting proteins in NPC cells. Results:More >

    Graphic Abstract

    SIRT2 interacts with DDX24 to promote nasopharyngeal carcinoma growth

  • Open Access

    REVIEW

    Exploring exosomes to provide evidence for the treatment and prediction of Alzheimer’s disease

    XIANGYU QUAN, XUETING MA, GUODONG LI, XUEQI FU, JIANGTAO LI, LINLIN ZENG
    BIOCELL, Vol.47, No.10, pp. 2163-2176, 2023, DOI:10.32604/biocell.2023.031226
    (This article belongs to the Special Issue: Novel Biomarkers in Diseases for Detection, Diagnosis, and Prognosis)
    Abstract Exosomes are extracellular vesicles with a 30–150 nm diameter originating from endosomes. In recent years, scientists have regarded exosomes as an ideal small molecule carrier for the targeted treatment of Alzheimer’s disease (AD) across the blood-brain barrier due to their nanoscale size and low immunogenicity. A large amount of evidence shows that exosomes are rich in biomarkers, and it has been found that the changes in biomarker content in blood, cerebrospinal fluid, and urine are often associated with the onset of AD patients. In this paper, some recent advances in the use of exosomes in More >

    Graphic Abstract

    Exploring exosomes to provide evidence for the treatment and prediction of Alzheimer’s disease

Share Link